We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCVX icon
2526
Vaxcyte
PCVX
$8.81B
$307K ﹤0.01%
12,708
+1,127
+10% +$24.6K
WW
2527
DELISTED
WW International
WW
$306K ﹤0.01%
29,881
+13,060
+78% +$153K
EVOP
2528
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
$306K ﹤0.01%
13,253
+3,328
+34% +$79.1K
SRNE
2529
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$305K ﹤0.01%
130,715
+18,809
+17% +$58.7K
CNXN icon
2530
PC Connection
CNXN
$2.03B
$302K ﹤0.01%
+5,756
New +$272K
OLMA icon
2531
Olema Pharmaceuticals
OLMA
$915M
$302K ﹤0.01%
70,872
+700
+1% +$3.86K
PMVP icon
2532
PMV Pharmaceuticals
PMVP
$65.1M
$302K ﹤0.01%
14,504
-36,720
-72% -$648K
SLVM icon
2533
Sylvamo
SLVM
$1.54B
$302K ﹤0.01%
9,068
-29,819
-77% -$989K
GIL icon
2534
Gildan
GIL
$10.6B
$301K ﹤0.01%
8,021
+214
+3% +$8.39K
MAGN
2535
Magnera Corp
MAGN
$437M
$300K ﹤0.01%
1,862
+296
+19% +$58.6K
LGTY
2536
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
$300K ﹤0.01%
+14,387
New +$318K
FRST icon
2537
Primis Financial Corp
FRST
$414M
$299K ﹤0.01%
21,416
+7,700
+56% +$114K
UTI icon
2538
Universal Technical Institute
UTI
$1.44B
$299K ﹤0.01%
33,800
LEU icon
2539
Centrus Energy
LEU
$3.84B
$298K ﹤0.01%
8,834
+153
+2% +$6.42K
ENDP
2540
DELISTED
Endo International plc
ENDP
$298K ﹤0.01%
128,877
+5,121
+4% +$15K
ROCC
2541
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
$294K ﹤0.01%
8,509
+501
+6% +$16.4K
CEI
2542
DELISTED
Camber Energy, Inc
CEI
$294K ﹤0.01%
6,956
-155
-2% -$5.68K
CRAI icon
2543
CRA International
CRAI
$1.08B
$293K ﹤0.01%
3,480
-268
-7% -$23.5K
BTAI icon
2544
BioXcel Therapeutics
BTAI
$35.2M
$292K ﹤0.01%
872
+56
+7% +$16.2K
USNA icon
2545
Usana Health Sciences
USNA
$252M
$291K ﹤0.01%
3,657
+526
+17% +$47.4K
NGM
2546
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$290K ﹤0.01%
19,015
+795
+4% +$12.4K
AMRN
2547
Amarin Corp
AMRN
$299M
$289K ﹤0.01%
4,387
BCE icon
2548
BCE
BCE
$21.7B
$289K ﹤0.01%
5,200
FLGT icon
2549
Fulgent Genetics
FLGT
$513M
$289K ﹤0.01%
4,633
+1,411
+44% +$92.9K
FFAI
2550
Faraday Future Intelligent Electric
FFAI
$12.1M
0

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.